Movement disorders:帕金森病的运动和认知代谢网络之间的关系

2022-08-30 Freeman MedSci原创

通过delta量化的PDRP优势,可以检测出PD患者的功能障碍从运动网络向认知网络的扩散

尽管特发性帕金森病(iPD)患者的症状表现和疾病进展各不相同,但基本的组织病理学变化和所涉及区域的时间顺序是相对定型的。iPD与两个不同的代谢网络有关,即PD相关模式(PDRP)和PD相关认知模式(PDCP),它们分别与该疾病的运动和认知表现有关。用[18F]-氟脱氧葡萄糖(FDG)正电子发射断层扫描(PET)进行的纵向成像研究表明,PDCP在运动发病后4至6年开始明显升高。因此,与PDCP相比,在同一病人身上测量PDRP时,预计PDRP会有优势的表达。

 

图1: 论文封面图

在这种情况下,PDRP的优势可以从Braak最初描述的iPD的组织病理学变化的区域顺序来理解。疾病相关网络的异常甚至可能早于运动症状的出现,这一点从特发性快速眼动睡眠行为障碍(iRBD)患者的PDRP升高可以看出,这是一种前驱形式的疾病。相反,在非典型帕金森综合征(APS)中,如多系统萎缩(MSA)和进行性核上性麻痹(PSP),PDRP不可能占优势,Braak的顺序并不适用。


在这项研究中,斯洛文尼亚UMC Ljubljana的Tomaz Rus 等评估了不同病程的iPD患者的多个样本的PDRP优势,这些患者在四个不同的部位进行了FDG-PET扫描。对于每个病人,他们测量了PDRP和PDCP的表达水平,并计算了这些数值的差异,这被称为delta。我们研究了横断面iPD样本中delta与疾病持续时间的关系以及随着时间的推移。

同样,将iPD患者的delta与iRBD19受试者以及与LRRK2-G2019S突变相关的PD基因型和与疾病进展缓慢和更快相关的GBA1变体患者的相应数值进行比较。所得数据与APS患者中获得的相应措施进行了比较。最后,作为原则性证明,使用静止状态fMRI(rs-fMRI)非侵入性地获得类似的结果,证明了delta更广泛的应用潜力。

图2:论文结果图


他们使用[18F]-氟脱氧葡萄糖正电子发射断层扫描和静息态fMRI来量化delta,并比较不同样本的测量结果;同样在纵向的病人样本中评估delta随时间的变化。最后,评估了iRBD前驱个体和gPD受试者的delta。

四个iPD样本中的每一个Delta都异常升高(P < 0.05),在有风险的iRBD组中也是如此(P < 0.05),其数值随时间的推移而增加(P < 0.001)。

PDRP的优势也存在于gPD中,与侵略性较弱的LRRK2-G2019S突变相比,GBA1变体患者的数值更高(P = 0.005)

这一趋势在非典型帕金森综合征患者中没有观察到,根据PDRP的表达和delta(曲线下面积=0.85;P < 0.0001),他们与iPD的区别很准确。

该研究的重要意义在于发现了:通过delta量化的PDRP优势,可以检测出PD患者的功能障碍从运动网络向认知网络的扩散。因此,Delta可能有助于鉴别诊断和跟踪个别患者的疾病进展。

 


原文出处:
Rus T, Schindlbeck KA, Tang CC, et al. Stereotyped Relationship Between Motor and Cognitive Metabolic Networks in Parkinson’s Disease. _Movement Disorders_. Published online August 23, 2022:mds.29188. doi:[10.1002/mds.29188](https://doi.org/10.1002/mds.29188)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2013951, encodeId=ad03201395124, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 02 19:09:21 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077721, encodeId=75db20e7721f1, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Apr 08 19:09:21 CST 2023, time=2023-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784542, encodeId=1e291e8454237, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Nov 08 23:09:21 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878576, encodeId=987e18e8576d5, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Fri Nov 18 09:09:21 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738153, encodeId=740d1e381535c, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sun Sep 04 02:09:21 CST 2022, time=2022-09-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2013951, encodeId=ad03201395124, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 02 19:09:21 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077721, encodeId=75db20e7721f1, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Apr 08 19:09:21 CST 2023, time=2023-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784542, encodeId=1e291e8454237, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Nov 08 23:09:21 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878576, encodeId=987e18e8576d5, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Fri Nov 18 09:09:21 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738153, encodeId=740d1e381535c, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sun Sep 04 02:09:21 CST 2022, time=2022-09-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2013951, encodeId=ad03201395124, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 02 19:09:21 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077721, encodeId=75db20e7721f1, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Apr 08 19:09:21 CST 2023, time=2023-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784542, encodeId=1e291e8454237, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Nov 08 23:09:21 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878576, encodeId=987e18e8576d5, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Fri Nov 18 09:09:21 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738153, encodeId=740d1e381535c, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sun Sep 04 02:09:21 CST 2022, time=2022-09-04, status=1, ipAttribution=)]
    2022-11-08 cmsvly
  4. [GetPortalCommentsPageByObjectIdResponse(id=2013951, encodeId=ad03201395124, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 02 19:09:21 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077721, encodeId=75db20e7721f1, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Apr 08 19:09:21 CST 2023, time=2023-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784542, encodeId=1e291e8454237, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Nov 08 23:09:21 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878576, encodeId=987e18e8576d5, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Fri Nov 18 09:09:21 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738153, encodeId=740d1e381535c, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sun Sep 04 02:09:21 CST 2022, time=2022-09-04, status=1, ipAttribution=)]
    2022-11-18 anminleiryan
  5. [GetPortalCommentsPageByObjectIdResponse(id=2013951, encodeId=ad03201395124, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 02 19:09:21 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077721, encodeId=75db20e7721f1, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Apr 08 19:09:21 CST 2023, time=2023-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784542, encodeId=1e291e8454237, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Nov 08 23:09:21 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878576, encodeId=987e18e8576d5, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Fri Nov 18 09:09:21 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738153, encodeId=740d1e381535c, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sun Sep 04 02:09:21 CST 2022, time=2022-09-04, status=1, ipAttribution=)]

相关资讯

Movement disorders:血清MicroRNAs可预测孤立的快速眼动睡眠行为障碍和路易体疾病

仅特定的miRNA生物特征就有希望作为IRBD患者的进展生物标志物来预测PD和DLB的临床结果。

Movement disorders:大脑代谢与前驱和早期帕金森病中的多巴胺能失调有关

在前驱期和早期PD阶段,与多巴胺能神经支配有关的各个脑区的代谢反应的轨迹是不同的。

JAMA Netw Open:做好这两点,帕金森病患者全因死亡风险骤降65%!

 JAMA Netw Open:饮食和身体活动与帕金森病成人全因死亡率的关系

Movement disorders:湘雅医院:狗狗嗅一嗅,就能诊断帕金森病?

使用嗅探犬进行测试可能是一种有用的、无创的、快速的和具有成本效益的方法

JAMA子刊:高翔教授发现吃得对会运动,帕金森死亡率能降一半!

无论是健康饮食还是积极锻炼,都能充分保护帕金森患者的寿命。

Movement disorders:葡萄糖苷酶变体携带者和家族性帕金森病的性别频率差异

GBA PD总体上存在的男性性别优势在GBA变异的严重程度上并不一致,

拓展阅读

Nature Medicine:重塑帕金森病治疗前景:Prasinezumab在早期帕金森病快速进展亚型中的疗效分析

文章探讨了Prasinezumab这种单克隆抗体在早期帕金森病中的潜在的治疗作用。

【帕金森病专题分享】探索帕金森病进展及诊疗全攻略

帕金森病日来临之际,我们特别推出了帕金森病专题系列文章。无论你是初入此领域的新手,还是经验丰富的专家,这里都有你需要的知识和信息。点击立即阅读,共同提升帕金森病诊疗水平!

话题:帕金森病的真相你了解多少?

我们欢迎各位老师,学者们在下方评论区共同探讨帕金森病的各个方面,包括但不限于:帕金森病的介绍、早期症状、体征、预防等都可一起分享出来。

European Radiology:弥散基础频谱成像检测早期帕金森病黑质和白质束的病理改变

为了解决弥散张量成像的局限性,研究发展了弥散基谱成像 (DBSI)以粗量化各向异性扩散张量反映轴突的完整性,其在多种中枢神经系统疾病中的敏感性和准确性已被证实。

帕金森病睡眠量表修订版(PDSS-2)

帕金森病睡眠量表修订版(PDSS-2)

神经科一周速递:热点解读进展大盘点!

一周热点分享 ,紧跟神经科学前沿,让每一次诊疗都更精准,点击立即查看!

2024 NICE 诊断指南:帕金森病远程监测设备 [DG51]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2024-01-25

2023 NICE 技术鉴定指南:左旋多巴/卡比多巴组合治疗伴有运动症状的晚期帕金森病[TA934]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2023-11-29

帕金森病患者睡眠障碍评估与护理干预的最佳证据总结

浙江中医药大学护理学院 · 2023-08-10

早中期帕金森病患者运动管理的最佳证据总结

山东第一医科大学附属省立医院老年神经内科 · 2023-05-10